Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Precemtabart tocentecan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: Precemtabart tocentecan (Precem-TcT) Monotherapy | EXPERIMENTAL | - |
| Arm 2: Precem-TcT plus Bevacizumab | EXPERIMENTAL | - |
| Arm 3: Trifluridine/Tipiracil (FTD-TPI) plus Bevacizumab | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Precemtabart tocentecan | DRUG | Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle. |
| Bevacizumab | DRUG | Bevacizumab, administered intravenously every 3 weeks on Day 1 of each 21-day cycle or every 2 weeks on Day 1 and Day 15 of each 28-day cycle. |
| Trifluridine/Tipiracil (FTD-TPI) | DRUG | FTD-TPI, tablet, administered orally twice daily, on Days 1 to 5 and Days 8 to 12 of each 28-day cycle. |
Inclusion Criteria: * Participants with documented histopathological diagnosis of metastatic colorectal cancer, who were intolerant to, or whose disease was refractory to, or progressed after standard systemic therapies and no more than 2 previous systemic treatment regimens in the metastatic setti...
Top 20 of 76 competitors